Abbott Laboratories 2015 Annual Report Download - page 66

Download and view the complete annual report

Please find page 66 of the 2015 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

FINANCIAL REVIEW
ABBOTT 2015 ANNUAL REPORT
64
A comparison of significant product and product group sales is
asfollows. Percent changes are versus the prior year and are
basedon unrounded numbers.
(dollars inmillions) 2015 Total
Change Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals
Key Emerging Markets $2,781 17% (15)«% 32%
Other 939 28÷« (12)÷÷ 40÷«
Nutritionals—
International Pediatric
Nutritionals 2,378 1÷« (7)÷÷ 8÷«
U.S. Pediatric Nutritionals 1,592 4÷« —÷÷ 4÷«
International Adult
Nutritionals 1,729 (2)÷« (11)÷÷ 9÷«
U.S. Adult Nutritionals 1,276 (2)÷« —÷÷ (2)÷«
Diagnostics—
Immunochemistry 3,529 (2)÷« (10)÷÷ 8÷«
Vascular Products (1)—
Coronary Devices 2,176 (7)÷« (8)÷÷ 1÷«
Endovascular 520 (1)÷« (7)÷÷ 6÷«
(1) Coronary Devices include DES / BVS product portfolio, structural heart, guidewires,
balloon catheters, and other coronary products. Endovascular includes vessel closure,
carotid stents and other peripheral products.
(dollars inmillions) 2014 Total
Change Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals
Key Emerging Markets $2,383 4% (7)«% 11%
Other 735 27÷« (3)÷÷ 30÷«
Nutritionals—
International Pediatric
Nutritionals 2,362 5÷« (2)÷÷ 7÷«
U.S. Pediatric Nutritionals 1,533 (1)÷« —÷÷ (1)÷«
International Adult
Nutritionals 1,756 10÷« (4)÷÷ 14÷«
U.S. Adult Nutritionals 1,302 (3)÷« —÷÷ (3)÷«
Diagnostics—
Immunochemistry 3,614 5÷« (2)÷÷ 7÷«
Vascular Products (2)—
Coronary Devices 2,342 (3)÷« (2)÷÷ (1)÷«
Endovascular 527 11÷« (1)÷÷ 12÷«
(2) Coronary Devices include DES / BVS product portfolio, structural heart, guidewires,
balloon catheters, and other coronary products. Endovascular includes vessel closure,
carotid stents and other peripheral products.
RESULTS OF OPERATIONS
SALES
The following table details the components of sales growth by
reportable segment for the last three years:
Total %
Change
Components of % Change
Price Volume Exchange
Total Net Sales
2015 vs. 2014 0.8 (1.1) 10.2 (8.3)
2014 vs. 2013 3.0 (1.4) 6.9 (2.5)
Total U.S.
2015 vs. 2014 2.2 (1.5) 3.7 —
2014 vs. 2013 (1.4) (3.9) 2.5 —
Total International
2015 vs. 2014 0.2 (1.0) 13.1 (11.9)
2014 vs. 2013 5.0 (0.2) 8.9 (3.7)
Established Pharmaceutical Products Segment
2015 vs. 2014 19.3 0.3 33.8 (14.8)
2014 vs. 2013 9.0 2.1 12.8 (5.9)
Nutritional Products Segment
2015 vs. 2014 0.3 — 5.5 (5.2)
2014 vs. 2013 3.2 0.8 4.2 (1.8)
Diagnostic Products Segment
2015 vs. 2014 (1.6) (1.0) 8.3 (8.9)
2014 vs. 2013 3.9 (0.9) 7.3 (2.5)
Vascular Products Segment
2015 vs. 2014 (6.5) (4.0) 5.3 (7.8)
2014 vs. 2013 (0.9) (6.4) 6.9 (1.4)
The increases in Total Net Sales in 2015 and 2014 reflect unit
growth, partially oset by the impact of unfavorable foreign
exchange. The price declines related to Vascular Products sales
in2015 and 2014 primarily reflect pricing pressure on drug
eluting stents and other coronary products as a result of market
competition in the U.S. and other major markets. The impact
ofreimbursement reductions by the Centers for Medicare and
Medicaid Services on Abbott’s Diabetes Care business also con-
tributed to the overall 3.9% price decline in the U.S. in 2014.